https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
Plasma Fractionation Market Outlook with Focus
on Affordability and Access | 2032 Forecast
The plasma fractionation market revolves around the process of separating blood plasma into its
therapeutic components—such as immunoglobulins, clotting factors, albumin, and protease inhibitors—for
treating a variety of conditions like immune deficiencies, bleeding disorders, and neurological and pulmonary
diseases. The market is expanding steadily, driven by rising prevalence of autoimmune and hematological
disorders, growing geriatric populations, and increased healthcare access globally. North America holds a
dominant position due to strong collection networks and advanced infrastructure, while Asia-Pacific is
emerging rapidly thanks to expanding plasma collection and manufacturing capabilities. Continuing
challenges include high cost, complex manufacturing requirements, supply limitations of donor plasma, and
competition from recombinant alternatives.
According to Fortune Business Insights, the global plasma fractionation market was valued at USD 37.31
billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032,
exhibiting a compound annual growth rate (CAGR) of 8.8% during the forecast period. In 2024, North
America dominated the market with a 56.18% share.
Top Companies in the Market
CSL Behring (CSL) (U.S.)
Grifols, S.A (Spain)
Takeda Pharmaceutical Company Limited (Japan)
Kedrion S.p.A (Italy)
Octapharma (Switzerland)
ADMA Biologics, Inc. (U.S.)
Sartorius AG (Germany)
LFB (France)
Market Coverage & Competitive Landscape
This report provides comprehensive intelligence on the plasma fractionation industry, including:
Detailed market size and forecasts (2025–2032)
Segment analysis by end-user, product, and application
Regional breakdown across major geographies
Competitive landscape highlighting key players and strategic initiatives
Market drivers, restraints, and emerging trends
Leading companies such as CSL Behring, Grifols, Takeda, Octapharma, Kedrion, and others are
driving the competitive dynamics through capacity expansion, partnerships, and regulatory
approvals
Key Industry Development
In July 2024, Kedrion S.p.A. announced a framework for a long-term agreement with Biotest AG
for the full commercialization and distribution of the immunoglobulin therapy Yimmugo in the
U.S. market.
Market Drivers
Several factors are driving the growth of the plasma fractionation market:
Rising prevalence of chronic and immune-related diseases, including autoimmune and
bleeding disorders, which increases demand for plasma-derived therapies.
Advancements in plasma fractionation technologies improving efficiency and output.
Growing demand for immunoglobulin, albumin, coagulation factors, and protease
inhibitors to treat conditions such as immune deficiencies and trauma-related shock.
Restraints
The availability and safety of recombinant therapies pose a competitive challenge to
plasma-derived options by offering alternatives with lower risk of blood-borne
transmissions.
High production costs—entailing sophisticated equipment and skilled operations—limit
affordability and scalability, constraining market growth.
https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
Market Segments
Product Segments: Immunoglobulin segment leads market share, due to widespread
usage in treating immunodeficiency and autoimmune conditions.
Application Segments: Immunology & Neurology dominate. Critical Care ranks third,
propelled by demand for coagulation therapies following trauma.
End-user Segments: Hospitals & Clinics hold the highest revenue share; Clinical
Research Laboratories follow closely, driven by R&D in rare disease therapeutics. Others
(like academic and treatment centers) show slower growth.
Explore the full research report with detailed insights and
TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-
market-101614
Market Regional Insights
North America dominated with USD 20.96 billion in 2024, accounting for 56.18% of the global
market. This dominance stems from robust healthcare infrastructure, advanced plasma collection
networks, and strong presence of major players.
Europe held the second-largest share, supported by greater awareness of immunodeficiency
conditions, plasma collection initiatives, and strategic acquisitions such as Kedrion’s expansion
in the Czech Republic.
Asia Pacific is gaining momentum driven by growing pharmaceutical investments, rising
chronic disease burden, and improved healthcare access. Notable moves include Plasma Gen
Biosciences’ facility in Bangalore (May 2023).
Latin America, Middle East & Africa show relatively modest growth, though increasing
autoimmune disease prevalence and partnerships—for instance, GC BioPharma’s USD 90.48
million IVIG-SN supply contract with Brazil’s Blau Farmacêutica—point toward rising
opportunities.
Future Market Scope
The plasma fractionation market is poised for strong growth throughout the forecast period, with
the following trends expected to shape its future:
Continued expansion in the adoption of plasma-derived therapeutics to manage immune,
hematological, and trauma-related conditions.
Strengthening of infrastructure and plasma collection networks by key players to meet
growing demand.
Regulatory approvals and commercial agreements—such as Kedrion’s 2024 Yimmugo
deal—supporting new product penetration and geographical expansion.
Conclusion
The plasma fractionation market is on a strong growth trajectory, with an expected jump from
USD 37.31 billion in 2024 to USD 72.45 billion by 2032, growing at an 8.8% CAGR. North
America remains the dominant market while hospitals and clinics drive end-user growth.
Continued R&D, infrastructure expansion, and strategic alliances—which include Kedrion’s
U.S. agreement—are key to future market momentum. Stakeholders across the value chain
should stay informed and agile to capitalize on robust demand for plasma-derived therapies in
the years to come.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling
businesses of all sizes to make timely decisions. We offer customized solutions tailored to each
client’s needs, helping them address unique challenges. Our goal is to empower clients with
holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering
insights and recommendations that help them navigate technological and market changes. Our
consulting services are designed to help companies uncover hidden opportunities and address
competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com